Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Last updated: December 8, 2023
Sponsor: BioXcel Therapeutics Inc
Overall Status: Completed

Phase

3

Condition

Dementia

Manic Disorders

Williams Syndrome

Treatment

BXCL501

Matching Placebo

Clinical Study ID

NCT05271552
BXCL501-303
  • Ages > 65
  • All Genders

Study Summary

A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. All subjects must have a diagnosis of probable AD based on NIA-AA criteria (2018)
  2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)
  3. Subjects exhibit behaviors that are congruent with the International PsychogeriatricAssociation criterion for agitation representing a change from the subject's usualbehavior
  4. A score of 15 to 23 on the Mini-Mental State Exam (MMSE)
  5. Subjects who read, understand, and provide written informed consent, or who have a LARto provide consent on their behalf
  6. Subjects who are deemed to be medically appropriate for study participation by theprincipal investigator
  7. Participants who agree to use a medically acceptable and effective birth controlmethod

Exclusion

Exclusion Criteria:

  1. Subjects with dementia or other memory impairment not due to probable AD.
  2. Clinical diagnosis of probable AD should not be applied when there is evidence of acerebrovascular incident temporally related to the worsening of cognitive function.
  3. Subjects with agitation caused by acute intoxication.
  4. Subjects with significant risk of suicide or homicide per the investigator'sassessment.
  5. Subjects who are medically unstable or in recovery. Note: Subjects with a remote (>5years) history of stroke may be included, regardless of size/location.
  6. History of clinically significant syncope or syncopal attacks, orthostatic hypotensionwithin the past 2 years, current evidence of hypovolemia, orthostatic hypotension,bradycardia.
  7. Subjects who had a total score of >13 (ie, high fall risk) on the John Hopkins FallRisk Assessment Tool.
  8. Subjects with laboratory or ECG abnormalities.
  9. Subjects who have received an investigational drug within 30 days prior to Screening.
  10. Subjects who are currently suffering from substance abuse. Patients with a potentialcause for delirium (relatively recent onset agitation and dementia)

Study Design

Total Participants: 151
Treatment Group(s): 2
Primary Treatment: BXCL501
Phase: 3
Study Start date:
April 27, 2022
Estimated Completion Date:
April 21, 2023

Study Description

A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female subjects (65 years and older) with acute psychomotor agitation. Subjects will be dosed PRN with a maximum of 28 doses over a 12-week period. Once a subject has received 28 doses of BXCL501, they will continue to be followed for the remainder of the 12-week study period.

Approximately 150 subjects will participate in this study. Subjects will receive a single film consisting of BXCL501 40 µg dose or BXCL501 60 µg dose or placebo in a 1:1:1 randomization scheme. Subjects must reside in a care facility where all study-related procedures and study drug dosing will be performed.

Connect with a study center

  • BioXcel Clinical Research Site

    Phoenix, Arizona 85016
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Long Beach, California 90806
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Daytona Beach, Florida 32117
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Lady Lake, Florida 32159
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Maitland, Florida 32751
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    North Miami, Florida 33161
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Marrero, Louisiana 70072
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Springfield, Massachusetts 01103
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Berlin, New Jersey 08009
    United States

    Site Not Available

  • BioXcel Clinical Research Site

    Toms River, New Jersey 08755
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.